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SUMMARY 
In a study of lithium compliance in 35 patients with Manic Depressive Psychosis on prophylactic 
lithium it was found that insight into the nature of illness and drug compliance were unrelated. 
Prescription compliance is increasingly 
recognised as an important factor in the 
treatment of the mentally ill. The topic 
has been reviewed by Blackwell (1976). 
The specific problem of lithium non-
compliance has been dealt with by Van 
Putten (1973). It can be expected that 
knowledge of the nature of one's illness, 
i.e., insight would increase prescription 
compliance in spite of the side effects. 
This would be especially true in Manic 
depressive patients who are normal in 
the inter-morbid periods. The importance 
of insight in compliance has not so far re-
ceived sufficient attention. 
This paper presents our observations 
on the relationship between insight and 
lithium compliance in manic depressive 
patients. 
MATERIAL AND METHODS 
The study was done in 35 patients 
^on prophylactic lithium for Manic De-
pressive Psychosis for a period of not less 
than 6 months (range 6 months to 4 years) 
and had been treated as inpatients for 
at least four episodes of illness (mania and 
depression). The mean number of admis-
sion was 6.4^2.97. Serum lithium level 
was aimed at 5* 0.8 m Eq/L. 
The patients had all been informed of 
the side effects but no attempt was made 
to give them any explanation of their 
illness. 
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Insight was rated after elaborate ques-
tioning as per the P.S.E. (Wing et al., 1974) 
by two of the investigators and compliance 
was scored as per the schedule given in 
Appendix. Although interrogation for de-
termining compliance was carried out, re-
liance was placed on the serum lithium 
levels as they are truly objective data. 
Serum lithium levels had been determined 
at intervals ranging from 2 weeks to 12 
weeks, depending on the duration of treat-
ment. The number of serum lithium 
estimations carried out had a mean of 
16.38 and S. D. of 9.14. Patients with 
insight scores of 0 or 1 were grouped as 
those with insight and those with scores 
of 2 or more as those without insight. 
A correlation between compliance scores 
and the average insight scores as also a 
't' test of compliance scores in patients 
with and without insight was carried out. 
RESULTS 
The results are summarised in Table 
1. It can be seen that there is good inter-
TABLE 1 
I 
} 
r=0.8036 
d.f.=35 
r=0.0870 
d.f.=33 
1. Correlation between the 
insight scores by the 2 
raters. 
2. Correlation between 
average insight score 
and compliance score. 
3. Compliance scores in 
Patients with insight Mean=0.500 
Patients without insight Mean =0.667 
t=0.54, d.f.=33, N.S. 
p< 0.001 
p=N.S. 
s.d. = 1.02 
s.d.=0.79 
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rater reliability in the insight scores. There 
was poor correlation between insight scores 
and compliance scores and there was no 
significant difference in compliance scores 
in patients with and without insight. 
DISCUSSION 
It appears from the results that insight 
into the nature of illness does not seem 
to play a major role in lithium compliauce. 
It is possible that other factors like the 
socioeconomic ones play the major role in 
drug compliance. 
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APPENDIX I 
Compliance ratings : 
0—excellent .. Patient on regular medication on interrogation. All samples show serum lithium ^0.8m 
Eq/L. No relapse. 
1—good .. Patient accepts having missed from 1-3 doses/month. No sample or only one sample 
<0.8 m Eq/L. No relapse. 
2—fair .. More than one sample but less than 20% of samples show serum lithium levels <0.8 m 
Eq/L. 
3—poor .. More than 20% of samples <0.8 m Eq/L. 